FDA Accepts Sanofi's Sarclisa sBLA for Priority Review

In a significant development, the US Food and Drug Administration (FDA) has accepted Sanofi's supplemental Biologics Licence Application (sBLA) for priority review. The application pertains to Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for treating transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. This acceptance brings hope for a new frontline therapy for a group of patients with limited treatment options. The FDA is set to announce its decision on the approval by 27 September 2024.

The sBLA submission is backed by promising data from the global IMROZ Phase III clinical trial. This randomized, multicentre, open-label study involved 446 patients from 21 countries across 104 centers. The trial's primary endpoint was progression-free survival (PFS), and the interim analysis showed that the Sarclisa regimen significantly improved PFS compared to the standard VRd treatment alone. The safety profile of Sarclisa in the trial was consistent with previously reported data, providing further reassurance of its potential clinical use.

Sarclisa, a monoclonal antibody, aims to bolster the efficacy of the traditional VRd regimen. The positive trial results underscore its potential as a vital addition to the treatment arsenal for NDMM patients, particularly those ineligible for transplants who often face poor prognoses with current therapies.

Sanofi is also pursuing approval for Sarclisa from the European Union, which further emphasizes the global need for improved multiple myeloma treatments. Dietmar Berger, Sanofi Development’s global head and chief medical officer, expressed optimism regarding Sarclisa's potential impact. He highlighted the persistent need for new treatment options in multiple myeloma, especially for those who cannot undergo transplants and typically encounter worse outcomes. The FDA's acceptance for priority review and the promising trial results bolster Sanofi's confidence in Sarclisa as a potential best-in-class treatment.

In addition to its advancements with Sarclisa, Sanofi has recently entered a collaboration with Formation Bio and OpenAI to leverage artificial intelligence (AI) in accelerating drug development. This partnership aims to integrate data, software, and tailored AI models to create innovative solutions throughout the drug development process. The goal is to streamline the journey from drug discovery to bringing new medicines to patients more efficiently.

Sanofi's multifaceted approach—advancing promising therapies like Sarclisa and harnessing cutting-edge technology—demonstrates its commitment to addressing unmet medical needs and improving patient outcomes in challenging diseases like multiple myeloma. As the medical community awaits the FDA's decision, the potential approval of Sarclisa represents a beacon of hope for many patients and healthcare providers seeking more effective treatment options.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!